176 related articles for article (PubMed ID: 27197308)
1. A New Triglycyl Peptide Linker for Antibody-Drug Conjugates (ADCs) with Improved Targeted Killing of Cancer Cells.
Singh R; Setiady YY; Ponte J; Kovtun YV; Lai KC; Hong EE; Fishkin N; Dong L; Jones GE; Coccia JA; Lanieri L; Veale K; Costoplus JA; Skaletskaya A; Gabriel R; Salomon P; Wu R; Qiu Q; Erickson HK; Lambert JM; Chari RV; Widdison WC
Mol Cancer Ther; 2016 Jun; 15(6):1311-20. PubMed ID: 27197308
[TBL] [Abstract][Full Text] [Related]
2. Preclinical optimization of Ly6E-targeted ADCs for increased durability and efficacy of anti-tumor response.
Dela Cruz Chuh J; Go M; Chen Y; Guo J; Rafidi H; Mandikian D; Sun Y; Lin Z; Schneider K; Zhang P; Vij R; Sharpnack D; Chan P; de la Cruz C; Sadowsky J; Seshasayee D; Koerber JT; Pillow TH; Phillips GD; Rowntree RK; Boswell CA; Kozak KR; Polson AG; Polakis P; Yu SF; Dragovich PS; Agard NJ
MAbs; 2021; 13(1):1862452. PubMed ID: 33382956
[TBL] [Abstract][Full Text] [Related]
3. Rapid conjugation of antibodies to toxins to select candidates for the development of anticancer Antibody-Drug Conjugates (ADCs).
Hoffmann RM; Mele S; Cheung A; Larcombe-Young D; Bucaite G; Sachouli E; Zlatareva I; Morad HOJ; Marlow R; McDonnell JM; Figini M; Lacy KE; Tutt AJN; Spicer JF; Thurston DE; Karagiannis SN; Crescioli S
Sci Rep; 2020 Jun; 10(1):8869. PubMed ID: 32483228
[TBL] [Abstract][Full Text] [Related]
4. Antibody drug conjugates, targeting cancer-expressed EGFR, exhibit potent and specific antitumor activity.
Ho ECH; Qiu R; Miller E; Bilotta MT; FitzGerald D; Antignani A
Biomed Pharmacother; 2023 Jan; 157():114047. PubMed ID: 36459711
[TBL] [Abstract][Full Text] [Related]
5. Novel Thienoduocarmycin-Trastuzumab ADC Demonstrates Strong Antitumor Efficacy with Favorable Safety Profile in Preclinical Studies.
Valsasina B; Orsini P; Caruso M; Albanese C; Ciavolella A; Cucchi U; Fraietta I; Melillo N; Fiorentini F; Rizzi S; Salsa M; Isacchi A; Gasparri F
Mol Cancer Ther; 2023 Dec; 22(12):1465-1478. PubMed ID: 37722716
[TBL] [Abstract][Full Text] [Related]
6. Site-specific Antibody-Nitric Oxide Conjugate HN02 Possesses Improved Antineoplastic and Safety Properties.
Cheng T; Xie J; Yuan X; Guo M; Wu J; Wang M; Huang Z; Zhang J
J Immunother; 2024 Jun; 47(5):149-159. PubMed ID: 38557756
[TBL] [Abstract][Full Text] [Related]
7. Antibody drug conjugates beyond cytotoxic payloads.
Hobson AD
Prog Med Chem; 2023; 62():1-59. PubMed ID: 37981349
[TBL] [Abstract][Full Text] [Related]
8. Uncialamycin-based antibody-drug conjugates: Unique enediyne ADCs exhibiting bystander killing effect.
Nicolaou KC; Rigol S; Pitsinos EN; Das D; Lu Y; Rout S; Schammel AW; Holte D; Lin B; Gu C; Sarvaiya H; Trinidad J; Barbour N; Valdiosera AM; Sandoval J; Lee C; Aujay M; Fernando H; Dhar A; Karsunky H; Taylor N; Pysz M; Gavrilyuk J
Proc Natl Acad Sci U S A; 2021 Jun; 118(25):. PubMed ID: 34155147
[TBL] [Abstract][Full Text] [Related]
9. Extracellular vesicles as modifiers of antibody-drug conjugate efficacy.
Barok M; Puhka M; Yazdi N; Joensuu H
J Extracell Vesicles; 2021 Feb; 10(4):e12070. PubMed ID: 33613875
[TBL] [Abstract][Full Text] [Related]
10. Exploring the Sensitivity of Antibody-Drug Conjugate Efficacy to the Selection of Payload, Antibody, and Cell line.
Rao M; Murali S; Amores D; Yu F; Tsourkas A
Bioconjug Chem; 2024 Jan; 35(1):115-124. PubMed ID: 38173338
[TBL] [Abstract][Full Text] [Related]
11. Use of Payload Binding Selectivity Enhancers to Improve Therapeutic Index of Maytansinoid-Antibody-Drug Conjugates.
Nguyen TD; Bordeau BM; Balthasar JP
Mol Cancer Ther; 2023 Nov; 22(11):1332-1342. PubMed ID: 37493255
[TBL] [Abstract][Full Text] [Related]
12. AGCM-22, a novel cetuximab-based EGFR-targeting antibody-drug-conjugate with highly selective anti-glioblastoma efficacy.
Li D; Sun X; Li Y; Shang C; Dong Y; Zhao R; Zhang H; Wang Z; Fan S; Ma C; Li X
Bioorg Med Chem; 2024 Mar; 102():117657. PubMed ID: 38428068
[TBL] [Abstract][Full Text] [Related]
13. Engineering CD276/B7-H3-targeted antibody-drug conjugates with enhanced cancer-eradicating capability.
Feng Y; Lee J; Yang L; Hilton MB; Morris K; Seaman S; Edupuganti VVSR; Hsu KS; Dower C; Yu G; So D; Bajgain P; Zhu Z; Dimitrov DS; Patel NL; Robinson CM; Difilippantonio S; Dyba M; Corbel A; Basuli F; Swenson RE; Kalen JD; Suthe SR; Hussain M; Italia JS; Souders CA; Gao L; Schnermann MJ; St Croix B
Cell Rep; 2023 Dec; 42(12):113503. PubMed ID: 38019654
[TBL] [Abstract][Full Text] [Related]
14. Production and characterization of a camelid single domain anti-CD22 antibody conjugated to DM1.
Ziaei V; Ghassempour A; Davami F; Azarian B; Behdani M; Dabiri H; Habibi-Anbouhi M
Mol Cell Biochem; 2024 Mar; 479(3):579-590. PubMed ID: 37129769
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and Pharmacodynamics of TAK-164 Antibody Drug Conjugate Coadministered with Unconjugated Antibody.
Menezes B; Khera E; Calopiz M; Smith MD; Ganno ML; Cilliers C; Abu-Yousif AO; Linderman JJ; Thurber GM
AAPS J; 2022 Oct; 24(6):107. PubMed ID: 36207468
[TBL] [Abstract][Full Text] [Related]
16. Stepping forward in antibody-drug conjugate development.
Jin Y; Schladetsch MA; Huang X; Balunas MJ; Wiemer AJ
Pharmacol Ther; 2022 Jan; 229():107917. PubMed ID: 34171334
[TBL] [Abstract][Full Text] [Related]
17. Design and Evaluation of ZD06519, a Novel Camptothecin Payload for Antibody Drug Conjugates.
Petersen ME; Brant MG; Lasalle M; Das S; Duan R; Wong J; Ding T; Wu KJ; Siddappa D; Fang C; Zhang W; Wu AML; Hirkala-Schaefer T; Garnett GAE; Fung V; Yang L; Hernandez Rojas A; Lawn SO; Barnscher SD; Rich JR; Colombo R
Mol Cancer Ther; 2024 May; 23(5):606-618. PubMed ID: 38354417
[TBL] [Abstract][Full Text] [Related]
18. Generation and Characterization of Iduronidase-Cleavable ADCs.
Jäger S; Könning D; Rasche N; Hart F; Sensbach J; Krug C; Raab-Westphal S; Richter K; Unverzagt C; Hecht S; Anderl J; Schröter C
Bioconjug Chem; 2023 Dec; 34(12):2221-2233. PubMed ID: 38054705
[TBL] [Abstract][Full Text] [Related]
19. Metal-based antibody drug conjugates. Potential and challenges in their application as targeted therapies in cancer.
Del Solar V; Contel M
J Inorg Biochem; 2019 Oct; 199():110780. PubMed ID: 31434020
[TBL] [Abstract][Full Text] [Related]
20. Antibody-Mediated Delivery of Chimeric BRD4 Degraders. Part 2: Improvement of In Vitro Antiproliferation Activity and In Vivo Antitumor Efficacy.
Dragovich PS; Pillow TH; Blake RA; Sadowsky JD; Adaligil E; Adhikari P; Chen J; Corr N; Dela Cruz-Chuh J; Del Rosario G; Fullerton A; Hartman SJ; Jiang F; Kaufman S; Kleinheinz T; Kozak KR; Liu L; Lu Y; Mulvihill MM; Murray JM; O'Donohue A; Rowntree RK; Sawyer WS; Staben LR; Wai J; Wang J; Wei B; Wei W; Xu Z; Yao H; Yu SF; Zhang D; Zhang H; Zhang S; Zhao Y; Zhou H; Zhu X
J Med Chem; 2021 Mar; 64(5):2576-2607. PubMed ID: 33596073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
